|
|
| |
 |
Smallpox revaccination of 21000 first responders in Israel: lessons learned
From Int J Infect Dis, published online Nov 17
|
|
|
Vaccinia virus strain NYVAC induces substantially lower and quantitatively different human antibody responses compared with strains Lister and Dryvax
|
|
|
Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox
From J Infect Dis, published online Nov 14
|
|
|
Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow fiber infection model (HFIM) system
From Antimicrob Agents Chemother, published online Oct 13
|
|
|
Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection
From PLoS Pathog, published online Sep 19
|
|
|
AHRQ Hospital Surge Model
Estimates hospital resources needed for disease or terror attack; released Sep 12
|
|
|
Inactivation of poxviruses by upper-room UVC light in a simulated hospital room environment
From PLoS ONE, published online Sep 10
|
|
|
Dual-probe real-time PCR assay for detection of variola or other orthopoxviruses with dried reagents
From J Virol Methods, published online Aug 22
|
|
|
Immunogenic properties of plant-derived recombinant smallpox vaccine candidate pB5
From Vaccine, published online Aug 13
|
|
|
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus
From Aug 5 Proc Natl Acad Sci
|
|
|
IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection
From Aug Curr Opin Mol Ther
|
|
|
An update on the development of drugs against smallpox
From Aug Curr Opin Investig Drugs
|
|
|
US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination
|
|
|
Clinical and immune response to undiluted and diluted smallpox vaccine
From Jul 12 Swiss Med Wkly
|
|
|
Mapping perceptions related to acceptance of smallpox vaccination by hospital emergency room personnel
From Jun Biosecur Bioterror
|
|
|
Genetic diversity-independent neutralization of pandemic viruses (eg, HIV), potentially pandemic (eg, H5N1 strain of influenza) and carcinogenic (eg, HBV and HCV) viruses, and possible agents of bioterrorism (variola) by enveloped virus neutralizing compounds (EVNCs)
|
|
|
Smallpox: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis
CIDRAP-authored overview, updated May 29 with new research
|
|
|
Evaluation of preterm births and birth defects in liveborn infants of US military women who received smallpox vaccine
From Birth Defects Res A Clin Mol Teratol, published online May 21
|
|
|
Human effector and memory CD+8 T-cell responses to smallpox and yellow fever vaccines
|
|
|
Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination
|
|
|
Genetic basis for adverse events after smallpox vaccination
From J Infect Dis, published online May 2 with accompanying commentary (below)
|
|
|
Learning to appreciate our differences
Commentary in J Infect Dis, published online May 2
|
|
|
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor
From May Antimicrob Agents Chemother
|
|
|
Laboratory-acquired vaccinia exposures and infections--United States, 2005-2007
|
|
